AIM: To investigate in vitro treatment with NVP-AEW541, a small molecule inhibitor of insulin-like growth factor-1 receptor (IGF-1R), in biliary tract cancer (BTC), since this disease is associated with a poor prognosis due to wide resistance to chemotherapeutic agents and radiotherapy. METHODS: Cell growth inhibition by NVP-AEW541 was studied in vitro in 7 human BTC cell lines by automated cell counting. In addition, the anti-tumoral mechanism of NVP-AEW541 was studied by Western blotting, cell cycle analysis and reverse transcription-polymerase chain reaction (RT-PCR). Anti-tumoral drug effect in combination with gemcitabine, 5-fluorouracil (5-FU) and Polo-like kinase 1 inhibitor BI2536 was also studied. RESULTS: In vitro treatment with NVP-AEW541 suppressed growth in all human BTC cell lines, however response was lower in gallbladder cancer. Treatment with NVP-AEW541 was associated with dephosphorylation of IGF-1R and AKT. In contrast, phosphorylation of p42/p44 and Stat3 and expression of Bcl-xL were inconsistently downregulated. In addition, treated cells showed cell cycle arrest at the G1/S-checkpoint and an increase in sub-G1 peak. Moreover, IGF-1R and its ligands IGF-1 and IGF-2 were co-expressed in RT-PCR, suggesting an autocrine loop of tumor cell activation. Combined with gemcitabine, NVP-AEW541 exerted synergistic effects, particularly at low concentrations, while effects of combination with 5-FU or BI 2536 were only additive. CONCLUSION: Our findings suggest that NVP-AEW541 is active against BTC in vitro and potentiates the efficacy of gemcitabine.
AIM: To investigate in vitro treatment with NVP-AEW541, a small molecule inhibitor of insulin-like growth factor-1 receptor (IGF-1R), in biliary tract cancer (BTC), since this disease is associated with a poor prognosis due to wide resistance to chemotherapeutic agents and radiotherapy. METHODS: Cell growth inhibition by NVP-AEW541 was studied in vitro in 7 human BTC cell lines by automated cell counting. In addition, the anti-tumoral mechanism of NVP-AEW541 was studied by Western blotting, cell cycle analysis and reverse transcription-polymerase chain reaction (RT-PCR). Anti-tumoral drug effect in combination with gemcitabine, 5-fluorouracil (5-FU) and Polo-like kinase 1 inhibitor BI2536 was also studied. RESULTS: In vitro treatment with NVP-AEW541 suppressed growth in all human BTC cell lines, however response was lower in gallbladder cancer. Treatment with NVP-AEW541 was associated with dephosphorylation of IGF-1R and AKT. In contrast, phosphorylation of p42/p44 and Stat3 and expression of Bcl-xL were inconsistently downregulated. In addition, treated cells showed cell cycle arrest at the G1/S-checkpoint and an increase in sub-G1 peak. Moreover, IGF-1R and its ligands IGF-1 and IGF-2 were co-expressed in RT-PCR, suggesting an autocrine loop of tumor cell activation. Combined with gemcitabine, NVP-AEW541 exerted synergistic effects, particularly at low concentrations, while effects of combination with 5-FU or BI 2536 were only additive. CONCLUSION: Our findings suggest that NVP-AEW541 is active against BTC in vitro and potentiates the efficacy of gemcitabine.
Authors: Karel Caca; Jürgen Feisthammel; Karen Klee; Andrea Tannapfel; Helmut Witzigmann; Christian Wittekind; Joachim Mössner; Frieder Berr Journal: Int J Cancer Date: 2002-02-01 Impact factor: 7.396
Authors: Niels Reinmuth; Wenbiao Liu; Fan Fan; Young D Jung; Syed A Ahmad; Oliver Stoeltzing; Corazon D Bucana; Robert Radinsky; Lee M Ellis Journal: Clin Cancer Res Date: 2002-10 Impact factor: 12.531
Authors: A Knuth; H Gabbert; W Dippold; O Klein; W Sachsse; D Bitter-Suermann; W Prellwitz; K H Meyer zum Büschenfelde Journal: J Hepatol Date: 1985 Impact factor: 25.083
Authors: Oliver Stoeltzing; Wenbiao Liu; Niels Reinmuth; Fan Fan; Alexander A Parikh; Corazon D Bucana; Douglas B Evans; Gregg L Semenza; Lee M Ellis Journal: Am J Pathol Date: 2003-09 Impact factor: 4.307
Authors: Carlos García-Echeverría; Mark A Pearson; Andreas Marti; Thomas Meyer; Juergen Mestan; Johann Zimmermann; Jiaping Gao; Josef Brueggen; Hans-Georg Capraro; Robert Cozens; Dean B Evans; Doriano Fabbro; Pascal Furet; Diana Graus Porta; Janis Liebetanz; Georg Martiny-Baron; Stephan Ruetz; Francesco Hofmann Journal: Cancer Cell Date: 2004-03 Impact factor: 31.743
Authors: Matthew P Cunningham; Hilary Thomas; Christopher Marks; Margaret Green; Zhen Fan; Helmout Modjtahedi Journal: Int J Oncol Date: 2008-11 Impact factor: 5.650
Authors: A Ullrich; A Gray; A W Tam; T Yang-Feng; M Tsubokawa; C Collins; W Henzel; T Le Bon; S Kathuria; E Chen Journal: EMBO J Date: 1986-10 Impact factor: 11.598
Authors: María Sol Brassesco; Julia Alejandra Pezuk; Andressa Gois Morales; Jaqueline Carvalho de Oliveira; Gabriela Molinari Roberto; Glenda Nicioli da Silva; Harley Francisco de Oliveira; Carlos Alberto Scrideli; Luiz Gonzaga Tone Journal: Cancer Biol Ther Date: 2013-05-31 Impact factor: 4.742
Authors: Chao Yang; Ming Xu; Huo-Jian Shen; Hong-Yi Zhu; Fu Li; Min He; Tao Chen; Jian Wang; Wei-Jin Shi; Fu Ji Journal: Int J Clin Exp Pathol Date: 2014-01-15
Authors: Amy L Myers; Lin Lin; Derek J Nancarrow; Zhuwen Wang; Daysha Ferrer-Torres; Dafydd G Thomas; Mark B Orringer; Jules Lin; Rishindra M Reddy; David G Beer; Andrew C Chang Journal: Oncotarget Date: 2015-09-22